

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Kandimalla et al.
Serial No.: 09/965,116
Examiner: Not Yet Assigned
Filed: September 26, 2001
Group Art Unit: 1632
Entitled: MODULATION OF IMMUNOSTIMULATORY
ACTIVITY OF IMMUNOSTIMULATORY
ANALOGS BY POSITIONAL CHEMICAL
CHANGES
Attorney Docket No.: HYB-005US2 (1006/006)

Assistant Commissioner for Patents
Washington, DC 20231

**POWER OF ATTORNEY BY ASSIGNEE OF ENTIRE INTEREST
REVOCATION OF PRIOR POWERS, CHANGE OF CORRESPONDENCE
ADDRESS, and CERTIFICATE UNDER 37 C.F.R. 3.73(b)**

Sir:

The undersigned Assignee of the above-identified United States patent application hereby revokes all powers of attorney previously created and appoints the following attorneys with full power of substitution and revocation to prosecute the application and to transact all business in the Patent and Trademark Office connected therewith:

Wayne A. Keown, Ph.D. Reg. No. 33,923
Robert McIsaac, Ph.D. Reg. No. 46,918

All future correspondence should be sent to:

Keown & Associates
500 West Cummings Park
Suite 1200
Woburn, MA 01801
Telephone: 781-938-1805
Facsimile: 781-938-4777

#15/K.T.
4/8
Revoc.
w/P.O.A.

U.S.S.N. 09/965,116
Page 2

CERTIFICATE UNDER 37 C.F.R. 3.73(b)

Hybridon, Inc., a corporation existing under the laws of the State of Delaware, certifies that it is the Assignee of the entire right, title and interest in the patent identified above by virtue of an Assignment from the inventor(s) of the patent application recorded in the United States Patent and Trademark Office on June 19, 2002 at Reel 013014, Frame 0939.

The undersigned has reviewed all the documents in the chain of title of the patent application identified above, and, to the best of the undersigned's knowledge and belief, title is in the Assignee identified above.

The undersigned whose title is supplied below is empowered to act on behalf of the Assignee.

The undersigned further declares that all statements made herein are of its own knowledge and are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the patent.

Respectfully submitted,

By: R.G. ANDERSEN
Title: CFO
Signature: [Signature]
Date: 10 MARCH 2003